The FDA accepted a new drug application for a single inhaler that contains beclomethasone dipropionate, formoterol fumarate ...
Amgen and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE® (tezepelumab-ekko) for the add-on maintenance treatment of inadequately controlled chronic ...
Among adults with COPD and type 2 inflammation, having a history of cardiovascular or metabolic disease did not change ...
The FDA has accepted for review the NDA for Chiesi’s single inhaler triple therapy for the maintenance treatment of asthma in adults.
Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback